Back to search

National and Kapodistrian University of Athens

Αντιμετώπιση του οιδήματος της ωχράς λόγω απόφραξης κεντρικής φλέβας αμφιβληστροειδούς με ενδοϋαλοειδική έγχυση του αντι-αγγειογενετικού παράγοντα ranibizumab (lucentis)

Abstract

dc:description

Background/Purpose: To evaluate the effect of individualized repeated intravitreal injections of ranibizumab(Lucentis) on visual acuity (VA) and central foveal thickness (CFT) for central retinal vein occlusion (CRVO)-induced macular edema.Methods: Our study was a prospective interventional case series. Twelve eyes of 12 consecutive patientsdiagnosed with CRVO-related macular edema (nine perfused, three ischemic CRVO) treated with repeated (whenCFT was >220 κm) intravitreal injections of ranibizumab as a monotherapy within 3 months of onset wereevaluated. Optical coherence tomography (OCT) and fluorescein angiography (FA) were performed monthly andevery 3 months respectively. Changes in VA (ETDRS) and CFT were analyzed using the student’s paired t-test.Results: The mean time from diagnosis until injection was 80 days (2.7 months; range, 63-90 days) and the followup time was 12 months. In total, 89 injections were performed (mean 7.4). The mean CFT improved from 480±166κm at baseline to 230±33 κm (P<0.001) at the end of the follow-up. During the same period, of the 12 eyes, eight(67%) demonstrated improved VA (>0.3 LogMAR change, >15 letters), three (25%) stable VA and one (8%) worseVA as compared to baseline. None of the nine patients with perfused CRVO were converted to ischemic at 12months and one of the three eyes with ischemic CRVO (33.3%) developed iris neovascularization despite tworanibizumab injections. No ocular or systemic side effects were noted.Conclusion: Individualized repeated intravitreal injections of ranibizumab have shown promising results in VAimprovement and decrease in CFT in patients with macular edema associated with CRVO. Further studies areneeded in order to elucidate the role of intravitreal lucentis in the ischemic form of CRVO and its efficacy inpreventing conversion from the perfused to the ischemic form of the disease.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2015

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Mitsopoulou, Maria
  • Μητσοπούλου, Μαρία

Subjects

dc:subject × 13

Rights

dc:rights
Statement dc:rights
  • BY_NC_SA
Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/42533

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Mitsopoulou, Maria; Μητσοπούλου, Μαρία. Αντιμετώπιση του οιδήματος της ωχράς λόγω απόφραξης κεντρικής φλέβας αμφιβληστροειδούς με ενδοϋαλοειδική έγχυση του αντι-αγγειογενετικού παράγοντα ranibizumab (lucentis). National and Kapodistrian University of Athens, 2015. http://hdl.handle.net/10442/hedi/42533